IFNA1 antibody
Quick Overview for IFNA1 antibody (ABIN6937475)
Target
See all IFNA1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Specificity
- This MAb is specific for human interferon alpha 1 and does not cross react with human interferon alpha 2. Interferons are widely used therapeutic agents because of their anti-tumor and anti-viral effects and because of their modulatory effects on the immune system. These cytokines produce their effects by binding to the Type 1 Interferon- Receptor (IFNAR1). Down regulation of this receptor plays a key role in determining the magnitude and duration of cytokine signaling. This down regulation is influenced by phosphorylation of Serine 535 and 539 in the IFNAR1.
-
Cross-Reactivity (Details)
- Human.
-
Purification
- 1.0mg/ml of Ab purified from Bioreactor by Protein A/G.
-
Immunogen
- Purified recombinant human IFN-alpha1
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
-
Known_Application: Flow Cytometry (1-2 μg/million cells), Western Blot (1-2 μg/mL), Immunohistochemistry (frozen), Immunofluorescence (1-2 μg/mL), Optimal dilution for a specific application should be determined.
Positive_Control: Stimulated human peripheral blood mononuclear cells.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- Prepared in 10 mM PBS, WITHOUT BSA and Azide.
-
Preservative
- Azide free
-
Storage
- -20 °C,-80 °C
-
Storage Comment
- Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.
-
Expiry Date
- 24 months
-
-
- IFNA1 (Interferon, alpha 1 (IFNA1))
-
Alternative Name
- IFNA1
-
Background
-
IFN alpha, IFN alpha 1/13, IFN alpha 1b, Interferon alpha 13 (IFNA13), Interferon alpha leukocyte (IFL), Interferon alpha-1/13 (IFN-alpha-1/13), Interferon alpha-D (IFN alphaD), Interferon alpha1 (IFNA1), LeIF D,Interferon alpha-1 (IFNA1)
Cellular localisation: Cytoplasmic & Extracellular (Secreted) -
Molecular Weight
- 16-27kDa
-
Gene ID
- 3439, 37026, 533471
-
UniProt
- P01562
-
Pathways
- JAK-STAT Signaling, Hepatitis C
Target
-